Age-male-albumin-bilirubin-platelet score stratifies hepatocellular carcinoma risk after sustained virological response in hepatitis C-related compensated advanced chronic liver disease

Figure 1 Flowchart of patient selection. cACLD: Compensated advanced chronic liver disease; DAA: Direct-acting antiviral; HCC: Hepatocellular carcinoma; HCV: Hepatitis C virus; SVR12: Sustained virological response at 12 weeks after treatment completion; SVR: Sustained virological response.

Figure 2 Time-dependent receiver operating characteristic curves of four noninvasive scoring systems for predicting de novo hepatocellular carcinoma at 1-year, 3-year, 5-year, and 8-year follow-up. A: 1-year follow-up; B: 3-year follow-up; C: 5-year follow-up; D: 8-year follow-up. ALBI: Albumin-bilirubin score; aMAP: Age-male-albumin-bilirubin-platelet score; APRI: Aspartate aminotransferase-to-platelet ratio index; FIB-4: Fibrosis-4 index; ROC: Receiver operating characteristic; FU: Follow-up.

Figure 3 Kaplan-Meier curves. A: Kaplan-Meier curves of hepatocellular carcinoma risk according to empirically derived age-male-albumin-bilirubin-platelet (aMAP) score strata. Patients were stratified into low-, intermediate-, and high-risk groups using thresholds of < 55, 55 to < 60, and ≥ 60, respectively; B: Kaplan-Meier curves of hepatocellular carcinoma risk according to the originally validated aMAP score strata. Patients were stratified into low-, intermediate-, and high-risk groups using thresholds of < 50, 50 to < 60, and ≥ 60, respectively. aMAP: Age-male-albumin-bilirubin-platelet score.